Conference Day One

7:00 am Check In & Morning Coffee

7:55 am Chair’s Opening Remarks

Exploring the Current State of Play in Inflammasome Clinical Development to Drive Innovation & Benchmark Existing Research

8:00 am Detailing the Promising Clinical Outcomes from Phase 2 Trial of VTX2735 in Cryopyrin-Associated Periodic Syndromes (CAPS)

  • John Nuss Chief Scientific Officer, Ventyx Biosciences


  • Exploring the clinical validation of VTX2735 in CAPS with topline phase 2 data showing an 85% mean reduction in Key Symptom Score, affirming VTX2735’s potential as a peripheral NLRP3 inhibitor for CAPS treatment
  • Exploring VTX2735’s potential in cardiovascular diseases, with a focus on MACE prevention and recurrent pericarditis an opportunity to address unmet medical needs

8:30 am Examining Structurally Differentiated VENT-02 & Brain-Penetrant NLRP3 Inhibitor for Treatment of Neuroinflammatory Diseases


  • Exploring the unique structural characteristics of VENT-02, a novel NLRP3 inhibitor designed for neuroinflammatory diseases
  • Investigating the potential of VENT-02 as a brain-penetrant therapeutic agent targeting the NLRP3 inflammasome
  • Assessing the preclinical data supporting the efficacy and safety profile of VENT-02 in treating neuroinflammatory conditions

9:00 am Harnessing the Potential of Dual Inhibition: Targeting NLRP3 & NLRC4 Inflammasomes for Therapeutic Intervention


  • Revealing the collaboration between NLRP3 and NLRC4 inflammasomes in triggering inflammation linked to lupus, macular degeneration, Alzheimer’s, and multiple sclerosis
  • Demonstrating the efficacy of inflammasome blockade in animal models of macular degeneration and lupus patients, promising disease prevention and inflammation reduction
  • Exploring Phase 1 trial initiation for evaluation of Kamuvudine-8 in Geographic Atrophy

9:30 am Speed Networking


This informal session provides the perfect opportunity to connect with the industry frontrunners and key opinion leaders focusing on Inflammasome Therapeutics. Establish meaningful connections to build upon for the rest of the conference and gain exclusive first-hand insights into the latest research and developments driving progression across the Inflammasome field.

10:15 am Morning Break

Distilling the Latest Inflammasome Research to Move Beyond Robust & Validated Targets to Promising Novel Targets

10:30 am Exploring Novel Modalities: Disabling the NLRP3 Inflammasome with a NEK7 Molecular Glue Degrader

  • Alison Paterson Vice President, Discovery Biology,, Monte Rosa Therapeutics


  • Utilizing a NEK7 molecular glue degrader (MGD) as a potent and selective approach to targeting the NLRP3 inflammasome
  • Path to the clinic with a NEK7 MGD
  • NEK7 MGDs have tuneable tissue distribution profiles and can be highly brain penetrant

11:00 am Exploring the Non-Canonical Caspase-4 Inhibitor as a Novel Target for Inhibiting the Inflammasome


  •  Session Details TBC

11:30 am Session Reserved for Promega

12:00 pm Leveraging the Power of ASOs to Target the Expression of NLRP3 for Enhanced Specificity of Inflammasome Inhibition


  • Utilizing ASOs to specifically target NLRP3 expression for comprehensive inflammasome inhibition
  • Demonstrating potent reduction in Caspase-1 activity and complete blockade of mature IL-1β release with NLRP3-specific ASOs
  • Systemic administration of NLRP3-specific ASOs in a mouse model of CAPS shows prolonged survival and significant reduction in systemic inflammation, paving the way for potential ASO therapy in NLRP3-mediated diseases

12:30 pm Lunch Break

1:30 pm Leveraging Biochemical & Structural Analysis to Uncover Pyroptosis Inhibiting Nanobodies to Prevent Gasdermin D Pore Formation

  • Matthias Geyer Founding Director and Chair of the Institute of Structural Biology, Universitat Bonn


  • Exploring the effectiveness of six GSDMD-targeting nanobodies in inhibiting pore formation, elucidating their binding characteristics, stability, and impact on pyroptosis
  • Revealing the atomic-level interactions between human GSDMD and two nanobodies for detailed insights into their mode of action and epitope recognition 
  • Demonstrating the potential of nanobody-based intervention in preventing GSDMDmediated pore formation, presenting a promising avenue for developing therapeutics to modulate inflammasome-associated inflammation

2:00 pm Session Reserved for Alamar Biosciences

2:30 pm Leveraging Structural Insights to Design a Small Molecule ASC Inhibitor for Multi-Inflammasome Inhibition

  • Krishnan Nandabalan Founder, Chairman, President and Chief Executive Officer, Invea Therapeutics, Inc.


  • Unveiling a novel approach to multi-inflammasome inhibition through AI and ML technologies, targeting the apoptosis-associated speck-like protein containing a caspase activation and recruitment domain
  • Exploring the pivotal role of inflammasomes, including ASC, in initiating and controlling inflammatory responses across diverse IMIDs, paving the way for potential paradigm shifts in treatment strategies

3:00 pm Moving Beyond Symptom Suppression: Targeting NLRP3 Inflammasome for Disease Modification in Cardiac Conditions


  • Targeting the NLRP3 Inflammasome shifting towards addressing the root causes of cardiac conditions, moving beyond traditional symptom management approaches
  • Examining the complex interplay between inflammation, fibrosis, and disease progression
  • Exploring the promise in delaying disease recurrences and modifying the underlying pathophysiology of cardiac conditions

3:30 pm Uncovering the Link Between Endogenous Brain Steroids & Inflammasomes to Uncover Novel Mechanisms of Inhibiting the Inflammasome Pathway


  • GRX-917, through inducing endogenous neurosteroid production and inhibiting NLRP3 inflammation, presents a novel approach with potential benefits across neuropsychiatric, neurological, and autoimmune disorders
  • Exploring GRX-917’s improved pharmacokinetic profile derived from deuterium stabilization while maintaining efficacy and safety akin to its predecessor, Etifoxine

4:00 pm Afternoon Break & Poster Session


Immerse yourself in an engaging session in a relaxed atmosphere that encourages meaningful conversations and discussions. Explore a range of exciting poster presentations and showcase your own research and developments in the Inflammasome therapeutics space. Don’t miss out on the chance to connect, learn, and present. Get ready to be impressed!

Unveiling Molecular Mechanisms to Navigate the Challenges of Assessing Inflammasome Activity in Drug Development due to the Lack of Biomarkers

4:30 pm Examining Upstream Activators & Downstream Signals Beyond IL-1β & IL18 for Specific Markers of Specific Inflammasome Activation


  • Uncovering the challenges in utilizing cytokines as surrogate markers for inflammasome activity at the individual level
  • Explore cutting-edge technologies and methodologies for studying the molecular intricacies of inflammasome activation pathways for detection at the individual level
  • Discuss the potential of these technologies to provide deeper insights into the molecular details of individual inflammasomes and their activation patterns 

5:00 pm Investigating Structural & Molecular Details of Inflammasomes

  • Hao Wu Professor, Harvard Medical School


  • Activation pathway of the NLRP3 inflammasome
  • Activation mechanism of the NLRP3 inflammasome
  • New potential target for the NLRP3 inflammasome

5:30 pm Panel Discussion: Addressing the Biomarker Bottlenecks to Identify Areas of Progress: What is Needed?


  • Capitalize on this opportunity to collectively discuss and address the critical biomarker bottlenecks that Inflammasome therapeutics face
  • Alongside leading minds and industry pioneers, discuss the complexities associated with identifying and quantifying measures of inflammasomes using sophisticated biochemical techniques
  • Explore strategies for overcoming these challenges to facilitate translation into clinical practice

6:00 pm Chairs Closing Remarks & End of Day One